drugset
drugset / Trial / NCT04570436

Evaluating the Abuse Potential of NEURONTIN® When Taken Orally in Healthy Non-drug Dependent Participants With Sedative Drug Abuse Experience

NCT04570436 ↗

Phase 4 Completed 52 enrolled Viatris Specialty LLC
RandomizedCrossoverQuadruple-blindOther

Summary

This will be a randomized, double-blind, double-dummy, placebo- and active controlled, 5 treatment, 10 sequence, 5 period crossover single dose, Williams square design study in healthy adult, non drug dependent male and female participants with drug abuse experience with sedative drugs.

Timeline

Start
2021-03-29
Primary completion
2022-11-10
Completion
2022-11-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Diazepam Small molecule 20 mg Oral
Subject Gabapentin Unknown 600 mg Oral
Subject Gabapentin Unknown 1200 mg Oral
Subject Gabapentin Unknown 1800 mg Oral

Indications

substance abuse